Sorrento Therapeutics, Inc. (SRNE)
After hours:
| Previous close | 4.1700 |
| Open | 4.0800 |
| Bid | 3.7300 x 1800 |
| Ask | 3.7400 x 4000 |
| Day's range | 3.7400 - 4.1000 |
| 52-week range | 3.7400 - 17.2500 |
| Volume | |
| Avg. volume | 5,650,869 |
| Market cap | 1.166B |
| Beta (5Y monthly) | 2.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Sorrento Therapeutics Announces Covishield (Sti-9167), a Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346k) Variants of Sars-Cov-2
COVISHIELD (STI-9167) neutralizing antibody (nAb) was discovered by scientists from the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) and further optimized and engineered by Sorrento scientists.A preprint manuscript is published online at biorxiv.org: https://biorxiv.org/cgi/content/short/2022.01.19.476998v1Sorrento has obtained worldwide exclusive license rights from Icahn Mount Sinai as previously announced on March 9, 2021 (https://investors.sorrentotherapeutics.com/news-relea
- GlobeNewswire
Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico
Sorrento Therapeutics Mexico (“Sorrento Mexico”) distributed last week approximately one million COVISTIX tests in Mexico.Additional millions of COVISTIX tests are scheduled to be delivered to meet the ever-growing demand in Mexico.Tens of millions of COVISTIX tests are being manufactured to meet worldwide demands. SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and Sorrento Mexico today announced that approximately 1,000,000 COVISTIX tests wer
- GlobeNewswire
Sorrento Announces Completion of Enrollment in US Phase 2 Clinical Trial for COVI-DROPS and Achievement of Interim Analysis Threshold in the UK
COVID-19 patients with newly diagnosed SARS-CoV-2 infections were treated in these randomized, double-blind, placebo-controlled Phase 2 trials in the US and UK.COVI-DROPS™ neutralizing antibody was administered as a single low dose intranasal instillation.Results indicate COVI-DROPS is highly active against the original SARS-CoV-2 virus, as well as the variants of concern including highly transmissible and virulent Delta variant the dominant strain during the conduct of the trial. SAN DIEGO, Jan
